Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Ellinghaus

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Expert Review of Anticancer Therapy|November 25, 2025
Targeted therapy for biliary tract cancer: facts and fictions as well as demands and challengesDaniel Neureiter, Peter Ellinghaus, Matthias Ocker
Drug Discovery Today|December 14, 2011
What makes a good drug target?Isabella Gashaw, Peter Ellinghaus, Anette Sommer, et al.
Plos One|October 27, 2017
FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylaseIngo Flamme, Peter Ellinghaus, Diana Urrego, et al.
Drug Discovery Today|September 28, 2011
What makes a good drug target?Isabella Gashaw, Peter Ellinghaus, Anette Sommer, et al.
Cells|October 14, 2022
Patient Selection Approaches in FGFR Inhibitor Trials-Many Paths to the Same End?Peter Ellinghaus, Daniel Neureiter, Hendrik Nogai, et al.
The Journal of Sexual Medicine|September 25, 2007
Expression of messenger ribonucleic acid encoding for phosphodiesterase isoenzymes in human female genital tissuesStefan Uckert, Peter Ellinghaus, Knut Albrecht, et al.
Plos One|November 14, 2014
Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effectsIngo Flamme, Felix Oehme, Peter Ellinghaus, et al.
Molecular Medicine (Cambridge, Mass.)|January 7, 2011
Novel aspects of fibrin(ogen) fragments during inflammationCarla Jennewein, Nguyen Tran, Patrick Paulus, et al.
Cardiovascular Research|January 10, 2009
Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodellingStefan Schäfer, Peter Ellinghaus, Wiebke Janssen, et al.
Investigative Radiology|August 7, 2012
The osmolality of nonionic, iodinated contrast agents as an important factor for renal safetyDiana C Lenhard, Hubertus Pietsch, Martin A Sieber, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Expert Review of Anticancer Therapy|November 25, 2025
Targeted therapy for biliary tract cancer: facts and fictions as well as demands and challengesDaniel Neureiter, Peter Ellinghaus, Matthias Ocker
Drug Discovery Today|December 14, 2011
What makes a good drug target?Isabella Gashaw, Peter Ellinghaus, Anette Sommer, et al.
Plos One|October 27, 2017
FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylaseIngo Flamme, Peter Ellinghaus, Diana Urrego, et al.
Drug Discovery Today|September 28, 2011
What makes a good drug target?Isabella Gashaw, Peter Ellinghaus, Anette Sommer, et al.
Cells|October 14, 2022
Patient Selection Approaches in FGFR Inhibitor Trials-Many Paths to the Same End?Peter Ellinghaus, Daniel Neureiter, Hendrik Nogai, et al.
The Journal of Sexual Medicine|September 25, 2007
Expression of messenger ribonucleic acid encoding for phosphodiesterase isoenzymes in human female genital tissuesStefan Uckert, Peter Ellinghaus, Knut Albrecht, et al.
Plos One|November 14, 2014
Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effectsIngo Flamme, Felix Oehme, Peter Ellinghaus, et al.
Molecular Medicine (Cambridge, Mass.)|January 7, 2011
Novel aspects of fibrin(ogen) fragments during inflammationCarla Jennewein, Nguyen Tran, Patrick Paulus, et al.
Cardiovascular Research|January 10, 2009
Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodellingStefan Schäfer, Peter Ellinghaus, Wiebke Janssen, et al.
Investigative Radiology|August 7, 2012
The osmolality of nonionic, iodinated contrast agents as an important factor for renal safetyDiana C Lenhard, Hubertus Pietsch, Martin A Sieber, et al.
Pageof 4